Abstract

Objective: To explore the clinical effectiveness and safety of trastuzumab combined with chemotherapy in breast cancer patients. Methods: Eighty patients with postoperative local recurrence of breast cancer were divided into a control group (chemotherapy only) and an observation group (chemotherapy plus trastuzumab-targeted therapy). The clinical efficacy, adverse reactions, and complications were compared between groups. Results: The overall effective rate of clinical treatment in the observation group was higher than that in the control group (P < 0.05). The incidence of adverse reactions showed no difference between the groups (P > 0.05), while the complication rate was significantly lower in the observation group (P < 0.05). Conclusion: Trastuzumab-targeted therapy combined with chemotherapy can significantly improve clinical treatment outcomes for breast cancer patients, reduce the risk of complications, and maintain good safety, making it suitable for clinical promotion.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.